Amazon’s Jeff Bezos Has Gotten $9.5 Billion Richer This Year
The stock market has inched its way to one record high after another this year, with the S&P 500 gaining a solid if unspectacular 3.5 percent so far. That rise has enriched investors by some $900 billion in 2015, as Matt Krantz at USA Today points out.
As Krantz also notes, though, some shareholders have done far, far better than the broader market. Jeff Bezos, for example.
The Amazon CEO has benefitted from a 40 percent rise in his company’s stock in 2015, adding a whopping $9.5 billion in paper gains to his already sizable net worth to lift it to $38.2 billion, good enough for 11th highest in the world, according to Bloomberg’s Billionaires Index.
Related: 7 Quirky Economic Indicators – from Dogs to Guns
As well as Bezos has done, four foreign billionaires have actually made more in 2015: Pan Sutong, chairman of Hong Kong investment conglomerate Goldin Group, has made more than $20 billion; Wang Jianlin, the founder and chairman of another Chinese conglomerate, Dalian Wanda, has made $19.4 billion; Zhou Qunfei, China’s richest woman, has added nearly $11 billion; and Patrick Drahi, the French chairman and largest shareholder of Luxembourg-based telecom company Altice, has gained $9.7 billion.
Bezos may be far ahead of the U.S. pack, but the USA Today analysis of data from S&P Capital IQ shows some other CEOs of American companies have fared extremely well as a result of their stock holdings, too. Facebook’s Mark Zuckerberg has made more than $1 billion on paper, while Google’s Larry Page has gained just under $1 billion. And as shares of drugstore chain Walgreens Boots Alliance have surged more than 11 percent this year, acting CEO Stefano Pessina has profited to the tune of $645.6 million. The CEOs of salesforce.com, Under Armour, Starbucks, Mohawk Industries, Constellation Brands and Netflix have all seen paper gains of more than $260 million so far in 2015.
You can see USA Today’s full list here.
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
